research Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
Elagolix did not effectively treat polycystic ovary syndrome.
Search
for
Sort by
Research
60-90 / 1000+ results
research Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
research Alopecia associated with strontium ranelate use in a 62-year-old woman
A woman experienced hair loss after taking strontium ranelate for osteoporosis.
research Tamoxifen for flutamide/finasteride-induced gynecomastia
Tamoxifen effectively treats gynecomastia without causing impotence.
research Design, synthesis and structure-activity relationships studies on steroidal aromatase and 5α-reductase inhibitors as anti-tumors
Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
research No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
research Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
research 842Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS)
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
research Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice
Letrozole reduces seizures but not brain damage in mice.
research RU 58841, a new specific topical antiandrogen: A candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism
RU 58841 may treat acne, hair loss, and excessive hair growth.
research Reduced estradiol synthesis by letrozole, an aromatase inhibitor, is protective against development of pentylenetetrazole-induced kindling in mice
Letrozole may help prevent seizures by reducing certain hormone levels.
research Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
The inhibitor affects androgen metabolism but not ovarian function.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Experimental Evaluation of 3-meta-Pyridine-1,2,4-Oxadiazole Derivative of Deoxycholic Acid as a Prototype of 5-α-Reductase Inhibitors in In Silico and In Vivo Models
The new compound may be a safer alternative to finasteride for prostate protection.
research News & Notes
Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
research The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
research Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
research Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin
Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.
research Novel 5α-Reductase Inhibitors: Synthesis, Structure−Activity Studies, and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids
A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
research A case of aromatase inhibitor‐induced alopecia successfully treated with low‐dose oral minoxidil
Low-dose oral minoxidil improved hair growth when topical treatments failed.
research New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors.
Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq”
Generic Palbociclib is safe and tolerable for treating certain breast cancer types.
research Experimental Assessment of 3-meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors in silico and in vivo Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.